scholarly journals EEG synchrony analysis for early diagnosis of Alzheimer's disease: A study with several synchrony measures and EEG data sets

2009 ◽  
Author(s):  
J. Dauwels ◽  
F. Vialatte ◽  
C. Latchoumane ◽  
Jaeseung Jeong ◽  
A. Cichocki
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Diagnosis ◽  
Data Sets ◽  
Eeg Data

The Value of Quantitative EEG Measures in the Early Diagnosis of Alzheimer’s Disease

2011 ◽  
pp. 132-140
Author(s):  
Hideaki Tanaka
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Quantitative Eeg ◽  
Frequency Resolution ◽  
Parahippocampal Gyrus ◽  
Data Sets ◽  
Electromagnetic Tomography ◽  
Eyes Closed ◽  
Eeg Data ◽  
Z Value

There is growing interest in the discovery of clinically useful, robust biomarkers for Alzheimer’s disease (AD) and pre-AD; the ability to accurately diagnose AD or to predict conversion from a preclinical state to AD would aid in both prevention and early intervention. This study aimed to evaluate the usefulness of a statistical assessment of cortical activity using electroencephalograms (EEGs) with normative data and the ability of such an assessment to contribute to the diagnosis of AD. 15 patients with AD and 8 patients with mild cognitive impairment (MCI) were studied. Eyes-closed resting EEGs were digitally recorded at 200 Hz from 20 electrodes placed according to the international 10/20 system on the scalp, and 20 artifact-free EEG epochs lasting 2.56 ms were selected. Each EEG epoch was down-sampled to 100 Hz and matched to the normal data sets. The selected EEGs from each subject were analyzed by standardized Low Resolution Electromagnetic Tomography (sLORETA) and statistically compared with the age-matched normal data sets at all frequencies. This procedure resulted in cortical z values for each EEG frequency with 0.39 Hz frequency resolution for each subject. Some of the AD and MCI patients presented a peak of negative z value around 20 Hz, revealing hypoactivity of the parahippocampal gyrus and the insula in the sLORETA cortical image. In addition, severe cases of AD showed decreased parietal activation. These results were in agreement with evidence from statistical neuroimaging using MRI/SPECT. Submission of normal EEG data sets to sLORETA might be useful for the detection of diagnostic and predictive markers of AD and MCI in individual patients.

The Value of Quantitative EEG Measures in the Early Diagnosis of Alzheimer’s Disease

2012 ◽  
Vol 3 (4) ◽  
pp. 1-10
Author(s):  
Hideaki Tanaka
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Normative Data ◽  
Quantitative Eeg ◽  
Frequency Resolution ◽  
Parahippocampal Gyrus ◽  
Data Sets ◽  
Electromagnetic Tomography ◽  
Eyes Closed ◽  
Eeg Data

There is growing interest in the discovery of clinically useful, robust biomarkers for Alzheimer’s disease (AD) and pre-AD; the ability to accurately diagnose AD or to predict conversion from a preclinical state to AD would aid in both prevention and early intervention. This study aimed to evaluate the usefulness of a statistical assessment of cortical activity using electroencephalograms (EEGs) with normative data and the ability of such an assessment to contribute to the diagnosis of AD. 15 patients with AD and 8 patients with mild cognitive impairment (MCI) were studied. Eyes-closed resting EEGs were digitally recorded at 200 Hz from 20 electrodes placed according to the international 10/20 system on the scalp, and 20 artifact-free EEG epochs lasting 2.56 ms were selected. Each EEG epoch was down-sampled to 100 Hz and matched to the normal data sets. The selected EEGs from each subject were analyzed by standardized Low Resolution Electromagnetic Tomography (sLORETA) and statistically compared with the age-matched normal data sets at all frequencies. This procedure resulted in cortical z values for each EEG frequency with 0.39 Hz frequency resolution for each subject. Some of the AD and MCI patients presented a peak of negative z value around 20 Hz, revealing hypoactivity of the parahippocampal gyrus and the insula in the sLORETA cortical image. In addition, severe cases of AD showed decreased parietal activation. These results were in agreement with evidence from statistical neuroimaging using MRI/SPECT. Submission of normal EEG data sets to sLORETA might be useful for the detection of diagnostic and predictive markers of AD and MCI in individual patients.

Computer-aided methods for 3-D visualization of serial sections and thick biological specimens

1992 ◽  
Vol 50 (2) ◽  
pp. 1060-1061
Author(s):  
Mark Ellisman ◽  
Maryann Martone ◽  
Gabriel Soto ◽  
Eleizer Masliah ◽  
David Hessler ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Three Dimensional ◽  
Neuritic Plaque ◽  
Dimensional Structure ◽  
Data Sets ◽  
Molecular Physiology ◽  
Research Activities ◽  
Computer Aided ◽  
Dimensional Reconstruction

Structurally-oriented biologists examine cells, tissues, organelles and macromolecules in order to gain insight into cellular and molecular physiology by relating structure to function. The understanding of these structures can be greatly enhanced by the use of techniques for the visualization and quantitative analysis of three-dimensional structure. Three projects from current research activities will be presented in order to illustrate both the present capabilities of computer aided techniques as well as their limitations and future possibilities.The first project concerns the three-dimensional reconstruction of the neuritic plaques found in the brains of patients with Alzheimer's disease. We have developed a software package “Synu” for investigation of 3D data sets which has been used in conjunction with laser confocal light microscopy to study the structure of the neuritic plaque. Tissue sections of autopsy samples from patients with Alzheimer's disease were double-labeled for tau, a cytoskeletal marker for abnormal neurites, and synaptophysin, a marker of presynaptic terminals.

Race-Related Association between APOE Genotype and Alzheimer’s Disease: A Systematic Review and Meta-Analysis

2021 ◽  
pp. 1-10
Author(s):  
Wei Qin ◽  
Wenwen Li ◽  
Qi Wang ◽  
Min Gong ◽  
Tingting Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Black People ◽  
Late Onset ◽  
Meta Analysis ◽  
Group Analysis ◽  
Apoe Genotype ◽  
Cochrane Library ◽  
Data Sets ◽  
Apoe Genotypes

Background: The global race-dependent association of Alzheimer’s disease (AD) and apolipoprotein E (APOE) genotype is not well understood. Transethnic analysis of APOE could clarify the role of genetics in AD risk across populations. Objective: This study aims to determine how race and APOE genotype affect the risks for AD. Methods: We performed a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library since 1993 to Aug 25, 2020. A total of 10,395 reports were identified, and 133 were eligible for analysis with data on 77,402 participants. Studies contained AD clinical diagnostic and APOE genotype data. Homogeneous data sets were pooled in case-control analyses. Odds ratios and 95% confidence intervals for developing AD were calculated for populations of different races and APOE genotypes. Results: The proportion of APOE genotypes and alleles differed between populations of different races. Results showed that APOE ɛ4 was a risk factor for AD, whereas APOE ɛ2 protected against it. The effects of APOE ɛ4 and ɛ2 on AD risk were distinct in various races, they were substantially attenuated among Black people. Sub-group analysis found a higher frequency of APOE ɛ4/ɛ4 and lower frequency of APOE ɛ3/ɛ3 among early-onset AD than late-onset AD in a combined group and different races. Conclusion: Our meta-analysis suggests that the association of APOE genotypes and AD differ between races. These results enhance our understanding of APOE-related risk for AD across race backgrounds and provide new insights into precision medicine for AD.

A Transfer Learning Approach for Early Diagnosis of Alzheimer’s Disease on MRI Images

Neuroscience ◽  
2021 ◽  
Author(s):  
Atif Mehmood ◽  
Shuyuan yang ◽  
Zhixi feng ◽  
Min wang ◽  
AL Smadi Ahmad ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Diagnosis ◽  
Transfer Learning ◽  
Learning Approach

scholarly journals The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 371
Author(s):  
Patrycja Pawlik ◽  
Katarzyna Błochowiak
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Diagnostic Tool ◽  
Clinical Symptoms ◽  
Early Screening ◽  
Salivary Biomarkers

Many neurodegenerative diseases present with progressive neuronal degeneration, which can lead to cognitive and motor impairment. Early screening and diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are necessary to begin treatment before the onset of clinical symptoms and slow down the progression of the disease. Biomarkers have shown great potential as a diagnostic tool in the early diagnosis of many diseases, including AD and PD. However, screening for these biomarkers usually includes invasive, complex and expensive methods such as cerebrospinal fluid (CSF) sampling through a lumbar puncture. Researchers are continuously seeking to find a simpler and more reliable diagnostic tool that would be less invasive than CSF sampling. Saliva has been studied as a potential biological fluid that could be used in the diagnosis and early screening of neurodegenerative diseases. This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers are attempting to find correlations between specific biomarkers and early clinical symptoms, which could be key in creating new treatments for patients before the onset of symptoms.

Sign in / Sign up

Export Citation Format

Share Document